TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
2018 · Nature · 5,347 citations
https://doi.org/10.1038/nature25501
M
Michiel S. van der Heijden
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
340
Papers
26.1K
Citations
53
h-index
119
i10-index
Michiel S. van der Heijden is an academic researcher from University of Southern California. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Urinary and Genital Oncology Studies. The author has an h-index of 53, co-authored 289 publications.
ORCID: 0000-0002-4407-7881Papers by this author
worksAtezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
2017 · The Lancet · 1,400 citations
https://doi.org/10.1016/s0140-6736(17)33297-x
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · New England Journal of Medicine · 810 citations
https://doi.org/10.1056/nejmoa2312117
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
2024 · New England Journal of Medicine · 274 citations
https://doi.org/10.1056/nejmoa2408154
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy
2015 · European Urology · 215 citations
https://doi.org/10.1016/j.eururo.2015.01.014
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
2019 · Nature Communications · 207 citations
https://doi.org/10.1038/s41467-019-13084-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat